Supplementary Table S1.Failure- and progression-free survival at different time-points of the included trials
Trials / Failure/Progression -free survival, HR (95% CI)1-year / 2-year / 3-year / 4-year / 5-year
Failure-free survival / —
Rossi et al. 1988 [16] * / 0.99 (0.59–1.64) / 0.88 (0.58–1.33) / 0.88 (0.58–1.33) / 0.87 (0.57–1.32) / —
Chan et al. 1995 [17]† / 0.92(0.36–2.38) / 0.96(0.43–2.11) / 1.07 (0.55–2.12) / 1.07 (0.55–2.12) / 1.07 (0.55–2.12)
Cvitcovics et al. 1996 [18] / 0.83(0.60–1.15) / 0.67(0.51–0.89) / 0.70(0.53–0.92) / 0.71 (0.54–0.92) / 0.73 (0.57–0.95)
Chua et al. 2001 [21] / 0.78(0.41–1.47) / 0.81(0.51–1.29) / 0.82(0.54–1.25) / 0.80 (0.53–1.19) / 0.81 (0.55–1.21)
Hareyama et al. 2002 [23] † / 0.76(0.29–1.96) / 0.83(0.41–1.67) / 0.72 (0.38–1.36) / 0.72 (0.38–1.36) / 0.72 (0.38–1.36)
Chan et al. 2002, 2005 [25, 26] / 0.60(0.35–1.04) / 0.72(0.49–1.08) / 0.80 (0.56–1.14) / 0.80 (0.57–1.12) / 0.78 (0.57–1.08)
Lin et al. 2003 [27] / 0.30(0.14–0.62) / 0.57(0.35–0.94) / 0.60(0.39–0.93) / 0.58 (0.38–0.89) / 0.56 (0.37–0.86)
Kwong et al. 2004 [28]‡
additional concurrent chemoradiotherapy / 0.62(0.36–1.06) / 0.71(0.45–1.13) / 0.75(0.48–1.17) / 0.77 (0.49–1.21) / 0.77 (0.49–1.20)
additional adjuvant chemotherapy / 0.91(0.54–1.53) / 0.95(0.62–1.47) / 1.02(0.67–1.55) / 1.01 (0.67–1.53) / 1.02 (0.68–1.54)
Lee et al. 2005, 2010 [29,30] / 0.43(0.23–0.80) / 0.60(0.40–0.91) / 0.61(0.43–0.87) / 0.62 (0.44–0.88) / 0.66 (0.47–0.92)
Lee et al. 2006, 2011 [32,33] / 1.72(0.30–9.85) / 1.13(0.45–2.87) / 0.96(0.41–2.27) / 0.92 (0.42–2.00) / 0.89 (0.46–1.73)
Chen et al. 2008, 2013 [34,35] / 0.29(0.12–0.70) / 0.57(0.34–0.94) / 0.63(0.41–0.98) / 0.64 (0.42–0.96) / 0.64 (0.44–0.94)
Huang et al. 2009, 2012 [36,37] / 1.40(0.78–2.50) / 1.16(0.79–1.71) / 1.05(0.75–1.49) / 1.06 (0.76–1.47) / 1.07 (0.78–1.46)
Hui et al. 2009 [38] / 0.53(0.15–1.83) / 0.43(0.14–1.29) / 0.49(0.20–1.19) / 0.48 (0.17–1.40) / 0.48 (0.17–1.40)
Chen et al. 2011 [39] / 0.47(0.12–1.86) / 0.44(0.12–1.63) / 0.47(0.17–1.31) / 0.51 (0.22–1.16) / 0.45 (0.23–0.88)
Xu et al. 2012, 2014[42,43] / 1.14(0.57–2.27) / 1.44(0.87–2.38) / 1.23(0.78–1.94) / 1.27 (0.84–1.91) / 1.20 (0.81–1.79)
Progression-free survival
Al-Sarraf et al. 1998 [19] / 0.19(0.09–0.38) / 0.35(0.22–0.54) / 0.33(0.22–0.51) / 0.38(0.25–0.56) / 0.35 (0.24–0.53)
Ma et al. 2001 [22] / 0.83 (0.49–1.40) / 0.81 (0.59–1.11) / 0.78 (0.59–1.03) / 0.77 (0.59–1.00) / 0.77 (0.59–1.00)
Chi et al. 2002 [24] / 0.78 (0.43–1.43) / 0.77 (0.48–1.23) / 0.79 (0.50–1.24) / 0.80 (0.52–1.25) / 0.80 (0.52–1.25)
Lee et al. 2005, 2010 [29,30] / 0.59 (0.36–0.96) / 0.69 (0.48–0.98) / 0.70 (0.47–1.04) / 0.68 (0.50–0.95) / 0.72 (0.53–0.98)
Wee et al. 2005 [31] / 0.69(0.38–1.25) / 0.56(0.35–0.88) / 0.57(0.38–0.87) / 0.57(0.38–0.84) / 0.55 (0.37–0.81)
Lee et al. 2006, 2011 [32,33] / 2.73 (0.50–14.81) / 1.02 (0.41–2.52) / 1.01 (0.43–2.39) / 0.95 (0.43–2.10) / 0.98 (0.53–1.81)
Chen et al. 2008, 2013 [34,35] / 0.27 (0.11–0.67) / 0.56 (0.34–0.93) / 0.58 (0.38–0.89) / 0.59 (0.40–0.88) / 0.65 (0.46–0.92)
Chen et al. 2012 [40] / 0.48 (0.25–0.92) / 0.74 (0.49–1.10) / 0.72 (0.49–1.05) / 0.72 (0.49–1.06) / 0.77 (0.55–1.10)
Fountzilas et al. 2012 [41] / 0.66 (0.35–1.27) / 0.66 (0.37–1.19) / 0.72 (0.41–1.27) / 0.74 (0.42–1.30) / 0.75 (0.43–1.31)
Abbreviations: HR, hazard ratio; CI, confidence interval.
*5-year failure-free survival wasnot available.
†Failure-free survival was calculated from the date of documented complete response.
‡ This trial was designed as a factorial 2 × 2 plan to test two comparisons: additional concurrent chemoradiotherapy, and additional adjuvant chemotherapy. Patients were divided into four treatment groups:Group A (radiotherapy alone, n = 55), Group B (concurrent chemoradiotherapy, n = 53), Group C (radiotherapy and adjuvant chemotherapy, n = 54), and Group D (concurrent chemoradiotherapy and adjuvant chemotherapy, n = 57).